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Abstract
The placenta is a remarkable organ. In normal pregnancy its specialized cells (termed
cytotrophoblasts) differentiate into various specialized subpopulations that play pivotal roles in
governing fetal growth and development. One cytotrophoblast subset acquires tumor-like
properties that allow the cells to invade the decidua and myometrium, a process that attaches the
placenta to the uterus.  The same subset also adopts a vascular phenotype that allows these fetal
cells to breach and subsequently line uterine blood vessels, a process that channels maternal blood
to the rest of the placenta. In the pregnancy complication preeclampsia, which is characterized by
the sudden onset of maternal hypertension, proteinuria and edema, cytotrophoblast invasion is
shallow and vascular transformation incomplete.  These findings, together with very recent
evidence from animal models, suggest that preeclampsia is associated with abnormal placental
production of vasculogenic/angiogenic substances that reach the maternal circulation with the
potential to produce at least a subset of the clinical signs of this syndrome. The current challenge
is to build on this knowledge to design clinically useful tests for predicting, diagnosing and treating
this dangerous disorder.
The investigative tools that are available to scientists have
radically changed over the past decade. New approaches,
such as the application of microarray and proteomics
techniques, have paved the way for major advances in
innumerable areas of medicine. But for a variety of rea-
sons, many aspects of human health and disease remain
very difficult to study and, consequently, are poorly
understood. Pregnancy is a prime example. True obstetri-
cal care does not begin until the second trimester when
the possibility of abortion declines. What is wrong with
this "wait and see" approach? The critical organogenesis
period, including formation of the placenta, occurs during
this interval, which remains, to a large extent, a "black
box." As a result there are very few clinical tests, other than
imaging approaches, to discriminate between pregnancies
that will progress normally and those that will be compli-
cated by numerous serious conditions such as preeclamp-
sia or preterm labor.
Whereas preterm labor primarily affects the health of the
fetus, preeclampsia also endangers the mother. As a result,
this pregnancy complication, which increases perinatal
mortality fivefold [1], is the leading cause of maternal
mortality in the Western world. The clinical diagnostic cri-
teria of this syndrome include the new onset of hyperten-
sion and the appearance of proteinuria and edema during
pregnancy, all of which could be explained by functional
alterations in the maternal vascular endothelium [2]. In a
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subset of cases the fetus stops growing, leading to intrau-
terine growth restriction.
Many researchers think that preeclampsia is actually an
end-stage disease, i.e., the final step in a chain of events
that is set in motion long before the signs of this condition
are evident, even before pregnancy. For example, pregnant
women with certain preexisting medical problems,
including an increased risk of thrombotic lesions (e.g.,
carriers of the factor V Leiden mutation [3]) and increased
oxidative stress [4], have an elevated risk of developing
this pregnancy complication. For the latter reason Poston
and co-workers tested the efficacy of antioxidants (vita-
mins C and E) in preventing the appearance of the signs
of preeclampsia [5]. Based on the initial encouraging
results reported in this study, the NIH has embarked on a
large-scale trial to test a similar preventive therapeutic reg-
imen in a much larger patient population.
Additionally, there is evidence that other factors that con-
tribute to the development of preeclampsia predate the
clinical condition. For example, preeclampsia and about
half the cases of intrauterine growth restriction are associ-
ated with particular placental pathologies. The extent of
interstitial invasion by cytotrophoblasts is variable but
frequently shallow, and endovascular invasion is consist-
ently rudimentary, making it extremely difficult to find
any maternal vessels that contain cytotrophoblasts [6,7].
Doppler ultrasound (in high-risk populations) shows that
women with reduced maternal blood flow to the placenta
that does not normalize by the end of the second trimester
are much more likely to develop preeclampsia [8]. This
finding suggests that the anatomical defects in placenta-
tion are present before the clinical signs.
These anatomical defects suggested to us that in preec-
lampsia, cytotrophoblast differentiation along the inva-
sive pathway is abnormal at a molecular level. We were
able to test this hypothesis because we already knew a
great deal about this process in normal pregnancy. In par-
ticular, our work shows that cytotrophoblast invasion of
the uterine wall entails an unusual ectoderm to vascular/
mesoderm transformation [9]. This principle is best illus-
trated by the cells' ability to carry out an intricate program
of adhesion molecule switching as they invade the uterine
wall. For example, cytotrophoblast progenitors, which
express adhesion molecules typical of many epithelial
cells,  e.g., E-cadherin and α6β4 integrin, downregulate
expression of these molecules as they differentiate and
acquire the ability to invade the uterus. In essence, they
replace their epithelial-like receptors with adhesion mole-
cules typical of endothelial cells, e.g., vascular endothelial
cadherin, vascular cell adhesion molecule-1, platelet-
endothelial cell adhesion molecule-1, and αVβ3 integrin.
Other aspects of the cell surfaces of invasive cytotrophob-
lasts also resemble vascular cells. For example, they
express urokinase plasminogen activator [10] and the
thrombin receptor [11].
Are defects in the ectoderm to vascular conversion associ-
ated with preeclampsia? Immunohistochemical analyses
of uterine wall biopsies obtained from women with this
syndrome showed that invasive cytotrophoblasts retain
expression of adhesion receptors characteristic of progen-
itor cells and fail to turn on receptors that promote inva-
sion and/or assumption of an endothelial phenotype [7].
For example, cytotrophoblasts in the uterine wall of preec-
lamptic patients failed to show strong staining for the
αVβ3, as did cytotrophoblasts that penetrated the spiral
arterioles. Preeclampsia also had a striking effect on
cytotrophoblast cadherin expression. In contrast to con-
trol samples, cytotrophoblasts in both the villi and
decidua showed strong reactivity with anti-E-cadherin,
and staining remained strong even on cytotrophoblasts
that had penetrated the superficial portions of uterine
arterioles. Strikingly, no VE-cadherin staining was
detected on cytotrophoblasts in any location in placental
bed specimens obtained from preeclamptic patients; nei-
ther cytotrophoblasts in the cell columns nor the few cells
that were found in association with vessels in the superfi-
cial decidua expressed VE-cadherin (data not shown).
However, staining for this adhesion molecule was
detected on maternal endothelium in the unmodified
uterine vessels in preeclamptic placental bed biopsy spec-
imens. Thus, cadherin modulation by cytotrophoblasts in
preeclampsia was defective, as shown by the persistence of
strong E-cadherin staining and the absence of VE-cadherin
staining on cytotrophoblasts in columns and in the super-
ficial decidua.
Given that cytotrophoblasts have the unusual ability to
mimic the cell surface properties of endothelial cells, we
went on to ask whether they also express molecules that
play important regulatory roles in conventional vasculo-
genesis and/or angiogenesis [12], principally vascular
endothelial growth factor (VEGF) family members.
Briefly, using a combination of in situ and  in vitro
approaches, we showed that cytotrophoblast differentia-
tion and invasion during the first and second trimesters of
pregnancy are associated with downregulation of VEGF
receptor (VEGFR)-2. Invasive cytotrophoblasts in early
gestation expressed VEGF-A, VEGF-C, placental growth
factor (PlGF), VEGFR-1 and VEGFR-3 and, at term, VEGF-
A, PlGF and VEGFR-1. In vitro the cells incorporated
VEGF-A into the surrounding extracellular matrix; PlGF
was secreted. We also found that cytotrophoblasts
responded to the VEGF ligands they produced. Blocking
ligand binding with soluble receptors significantly
decreased the cells' invasiveness, as monitored by their
ability to reach the underside of a Matrigel-coated filter,Reproductive Biology and Endocrinology 2004, 2:53 http://www.rbej.com/content/2/1/53
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due to a large increase in apoptosis, as monitored by
TUNEL staining.
Is preeclampsia associated with changes in cytotrophob-
last expression of VEGF family members? We used immu-
nolocalization techniques to characterize the cells'
expression of these ligands and receptors in tissue sections
of placental bed biopsies obtained from pregnant women
with severe forms of preeclampsia that necessitated deliv-
ery during the early third trimester. The results showed
that cytotrophoblast VEGF-A and VEGFR-1 staining
decreased, whereas staining for PlGF was unaffected.
Cytotrophoblast secretion of the soluble form of VEGFR-
1 in vitro increased. Together, the results of this study
showed that VEGF family members regulate cytotrophob-
last survival and that expression of a subset of family
members is misregulated in severe forms of preeclampsia.
We were particularly interested in these findings in light of
another of our published observations. Specifically, we
tested the hypothesis that the presence of abnormally dif-
ferentiated cytotrophoblasts within the uterine wall ulti-
mately leads a subpopulation of these cells dispersed
throughout the decidua to initiate programmed death
[13]. This phenomenon was particularly evident in
patients with the severest forms of preeclampsia. Specifi-
cally, we used the TUNEL method, which fluorescently
labels nicked ends of DNA, to visualize cells undergoing
apoptosis. Interestingly, fields of labeled cells were visual-
ized throughout the placental beds of these patients. We
hypothesize that this process, which in theory could lead
to rapid destruction of the maternal-fetal interface, may
contribute to the notoriously rapid development of the
symptoms, which since ancient times have been recog-
nized for the lightning-like speed with which they
appear–hence the name preeclampsia, derived from the
Greek eklampsis, sudden flash or development.
Subsequently, other investigators obtained direct evi-
dence in support of the theory that failed cytotrophoblast
invasion and pseudovasculogenesis are linked through
the abnormal production of VEGF family members to the
maternal vascular pathology. Specifically, Karumanchi
and co-workers [14] confirmed that placental production
(or release) of soluble VEGFR-1 (sFlt1) is increased in
preeclampsia. Moreover, they demonstrated that
increased levels of this receptor circulate in patients'
blood, a factor that is likely associated with a parallel
decrease in circulating levels of free PlGF. The placental
origin of VEGFR-1 was further demonstrated by showing
that it falls to normal levels after delivery. At a mechanistic
level they found that administration of soluble VEGFR-1
to pregnant rats induces hypertension, proteinuria, and
glomerular endotheliosis, lesions that are typically associ-
ated with preeclampsia. Thus, lowering circulating VEGF
levels can have profound effects. Furthermore, it is inter-
esting to note that this observation may also have clinical
utility. Specifically, as early as the first trimester of preg-
nancy, increased levels of soluble VEGFR-1 and decreased
levels of PlGF predict the subsequent development of
preeclampsia [15,16]. To date these data provide the
strongest evidence linking a defect in placentation to the
maternal systemic disorder.
In the midst of the excitement generated by the aforemen-
tioned findings, it is important to note that research into
the causes of preeclampsia has been bedeviled by over-
simplification and overgeneralization. It is certain that the
many forms of the disease (early vs. late gestation; severe
vs. mild [17]) reflect branch points or even different path-
ways in the pathogenesis process. For this reason it is
important to consider other credible theories that are not
necessarily mutually exclusive to the concept that imbal-
ances in placental production of angiogenic/vasculogenic
substances are associated with preeclampsia. For example,
Redman and co-workers showed that preeclampsia is
associated with an exaggeration of phenomena that are
associated with normal pregnancy. Examples include
maternal inflammatory responses [18] and deportation of
syncytiotrophoblastic microvillous membranes [19]. It is
interesting to note that addition of the latter membrane
fraction to cultured endothelial cells impairs their func-
tion [20].
Finally, it is important to consider the observations
described above in the context of the often repeated obser-
vation that preeclampsia is a disease of nulliparous
women; only a small subset of patients develop this con-
dition during subsequent pregnancies [21]. This fact has
been cited as evidence that preeclampsia is triggered by an
abnormal response to paternal antigens to which the
mother is tolerized during the affected pregnancy. This
theory also fits with the fact that a multiparous woman's
risk of developing preeclampsia returns to that of a prim-
igravida if she changes partners [22]. Recently, the latter
observation has been attributed to the interval between
pregnancies [23]. It is interesting to note that the
increased risk of preeclampsia that is associated with nul-
liparity and interpregnancy interval could also be
explained in terms of the placenta's ability to remodel the
uterine circulation. Like a conventional coronary angi-
oplasty, it is likely that the benefits of this process, which
commonly last for years, are eventually lost over time.
CONCLUSIONS
Preeclampsia, particularly the severe cases that occur early
in pregnancy, is associated with defects in the (placental)
cytotrophoblast differentiation pathway that leads to uter-
ine invasion. At a morphological level, interstitial inva-
sion is often shallow. Perhaps more significantly,Publish with BioMed Central    and   every 
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endovascular invasion, particularly the arterial compo-
nent, is rudimentary. The latter defect is thought to lead to
hypoperfusion of the placenta. At a molecular level, these
defects are associated with particular deficits in the differ-
entiation process whereby cytotrophoblasts–epithelial
cells of ectodermal origin–assume vascular-like proper-
ties. Until recently the question was how the latter defects
could lead to the maternal symptoms of this condition.
But a possible link in the form of preeclampsia-associated
changes in placental production of vasculogenic/ang-
iogenic substances has been discovered. It is likely that
this new paradigm will improve both diagnosis and treat-
ment of this life-threatening pregnancy complication.
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